Literature DB >> 8246768

Insulin and glucose suppress hepatic glycogenolysis by distinct enzymatic mechanisms.

Z Liu1, L B Gardner, E J Barrett.   

Abstract

Both insulin and hyperglycemia can effectively suppress hepatic glucose output (HGO). We examined whether insulin and hyperglycemia specifically suppress liver net glycogen breakdown in a rat model in which glycogen is the major source of HGO. We further examined whether insulin and hyperglycemia act by similar or distinct enzymatic mechanisms. HGO, the rate of net glycogen loss, and glycogen phosphorylase and synthase activities were measured in fed, anesthetized rats infused with saline or insulin (7 mU/min/kg) while either maintaining plasma glucose at basal (7.8 +/- 0.2 mmol/L, euglycemic clamp [EC]) or at 10 mmol/L above basal (18 +/- 0.4 mmol/L, hyperglycemic clamp [HC]). During the basal period, the rate of HGO in each group was comparable to the rate of net glycogen breakdown, averaging 76 +/- 9 and 75 +/- 5 mumol/min/kg, respectively. Thus glycogen breakdown appeared to be a major source of ongoing HGO. Over the last 60 minutes of the experimental period, the rate of glycogenolysis averaged 69 +/- 8 mumol/min/kg in saline-treated rats; this could account for about 80% of the total HGO. During both EC and HC studies, HGO was suppressed (5.5 +/- 3 and -3.6 +/- 10 mumol/min/kg, respectively; P < .001 for each). Net glycogen breakdown decreased by 50% in EC rats (P < .05) and ceased in HC rats (P < .001). Glycogen synthase was predominantly in the active form in all three experimental groups (87% +/- 2%, 89% +/- 2%, and 95% +/- 3% in saline, EC, and HC rats, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8246768     DOI: 10.1016/0026-0495(93)90149-i

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans.

Authors:  K F Petersen; D Laurent; D L Rothman; G W Cline; G I Shulman
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

2.  Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo.

Authors:  W H Martin; D J Hoover; S J Armento; I A Stock; R K McPherson; D E Danley; R W Stevenson; E J Barrett; J L Treadway
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

3.  Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells.

Authors:  N A Syed; R L Khandelwal
Journal:  Mol Cell Biochem       Date:  2000-08       Impact factor: 3.396

4.  Ranolazine recruits muscle microvasculature and enhances insulin action in rats.

Authors:  Zhuo Fu; Lina Zhao; Weidong Chai; Zhenhua Dong; Wenhong Cao; Zhenqi Liu
Journal:  J Physiol       Date:  2013-06-24       Impact factor: 5.182

5.  Metformin prevents endothelial oxidative stress and microvascular insulin resistance during obesity development in male rats.

Authors:  Jia Liu; Kevin W Aylor; Weidong Chai; Eugene J Barrett; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2022-02-07       Impact factor: 4.310

6.  Obese gene expression: reduction by fasting and stimulation by insulin and glucose in lean mice, and persistent elevation in acquired (diet-induced) and genetic (yellow agouti) obesity.

Authors:  T M Mizuno; H Bergen; T Funabashi; S P Kleopoulos; Y G Zhong; W A Bauman; C V Mobbs
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.